Johnson & Johnson (NYSE:JNJ) reported its first quarter earnings, with both revenue and profit beating Wall Street expectations driven by strong sales in its oncology portfolio, especially the multiple myeloma drug Darzalex.
Revenue was up 2.4% year-over-year at $21.89 billion, ahead of estimates of $21.56 billion.
Earnings per share (EPS) of $2.77 were up 2.2% from the year-ago quarter, compared to the consensus $2.58.
The company raised its 2025 sales outlook by $700 million to a range of $91.6 billion to $92.4 billion, reflecting the addition of the schizophrenia drug Caplyta from the recent Intra-Cellular acquisition.
It maintained its 2025 adjusted EPS guidance to a range of $10.50 to $10.70, implying growth of 6.2% at the midpoint, noting anticipated tariff impacts and acquisition-related costs.
“The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” CEO Joaquin Duato said in a statement.
“During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition.”